Ads Top

Covaxin gets expert panel’s nod for use on 2-18 year olds

Bharat Biotech said it had submitted data from the Phase 2/3 clinical trials in the 2-18 years age group for Covaxin (BBV152) to the Central Drugs Standard Control Organisation (CDSCO), that the data had been thoroughly reviewed by the CDSCO and SEC, and that they provided their positive recommendations.

from Lifestyle News:Entertainment News,Bollywood Latest News,Box Office Collection Report,Movie Reviews
Read The Rest:financialexpress...

No comments:

Powered by Blogger.